Alvotech (ALVO) Stock Price, Quote & News

Company Profile

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis ulcerative colitis, and other indicatio...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Website: www.alvotech.com

Address:

9, Rue de Bitbourg, Luxembourg, Luxembourg

time_to_snap Aug. 24 at 5:12 PM

$ALVO collecting biosimilars like Infinity Stones. FDA inspection closed, 3 major U.S. decisions lined up for Q4, and management still guides $650–700M revenue + $180–220M EBITDA for 2026. $ALVO is inevitable. 🫰

0 · Reply

notreload_ai Aug. 24 at 4:21 PM

BofA initiates Buy on $ALVO with $7 PT (58% upside). FDA clears Reykjavik plant as biosimilar launches drive commercial growth. https://notreload.xyz/xy/alvotech-bofa-initiates-buy-rating-as-biosimilar-launch-cycle-begins/

0 · Reply

G101SPM Aug. 24 at 3:59 PM

$ALVO $5.15 +0.72 Alvotech (ALVO) initiated with a Buy at BofA Securities, tgt $7 note: ) The Company signs Lotus Pharma deal for durvalumab and emicizumab biosimilars in U.S. and parts of Asia.

0 · Reply

JohnTill Aug. 24 at 3:37 PM

$ALVO I will definitely regret it but reduced the position by half now at 5.20-5.30 given the volume and % move. BOFA's $7 target in 2027 should be easy but I hate Sept/Oct. action overall and FDA news in not until late Dec. so playing things careful. Good luck to those long and this win is well deserved for those around for a while and understanding the play.

0 · Reply

time_to_snap Aug. 24 at 3:20 PM

$ALVO 🚀🚀🚀

0 · Reply

JohnTill Aug. 24 at 3:10 PM

$ALVO I cannot resist and locking in some for 62% gain right here. I know I will regret it down the road and that $8 gap is itching to get filled but this is WAY too much profit sitting in the account on this one now on a very large position. Congrats to those that held their ground.

0 · Reply

JohnTill Aug. 24 at 2:05 PM

$ALVO You just know more analysts are going to follow BofA with upgrades rather than risk looking stupid heading into 2027. Nice way to start the week. Just saw that magical “+50%” on my position, but I’m still sticking with my call that we get the gap fill and I get my “100%+.” Now I just need $LU to start behaving properly, especially since I made the mistake of making ALVO my #3 position instead of #1. I have been playing with some size in these so not complaining.

1 · Reply

FlyingChemist01 Aug. 24 at 1:26 PM

$ALVO I'm quite surprised of this price action, I wasnt expecting this surge.

2 · Reply

Windy007 Aug. 24 at 11:12 AM

$ALVO BofA initiated coverage of Alvotech with a Buy rating and $7 price target. The firm sees attractive risk/reward as Alvotech's multi-year investments begins to translate into a "higher-quality commercial growth story." Investor sentiment has been weighed down by regulatory uncertainty surrounding the Reykjavik manufacturing facility, but the FDA's closure of the inspection removes a key overhang on the stock and clears the path toward new approvals, the analyst tells investors in a research note. BofA says Alvotech is nearing an "important inflection point" as the investment debate shifts from regulatory risk toward commercial execution and revenue growth. 7:01 A

0 · Reply

JohnTill Aug. 21 at 2:27 PM

$ALVO Nice news and thanking my lucky stars that even after a few sales yesterday this remains my third largest position. I guess we did not have to wait until Dec. for the flood of good news. I have said it so many times that the gap at 8 get filled in 2027 but no I wonder if we see that before year end. Buyout getting more and more likely with each release.

0 · Reply

Alvotech initiated with a Buy at BofA

2026-08-21T13:35:10.000Z - 3 days ago

Alvotech enters licensing, commercialization agreement with Lotus Pharmaceutical

Aug 21, 2026, 9:00 AM EDT - 3 days ago

Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets

Aug 20, 2026, 8:00 AM EDT - 4 days ago

Alvotech Earnings Call Transcript: Q2 2026

Aug 20, 2026, 8:00 AM EDT - 4 days ago

Alvotech Earnings release: Q2 2026

Aug 20, 2026, 8:00 AM EDT - 4 days ago

Alvotech Slides: Q2 2026

Aug 19, 2026, 4:30 PM EDT - 4 days ago

Alvotech Announces Financial Results for the First Half of 2026 and Provides a Business Update

2026-08-16T13:48:38.000Z - 8 days ago

Alvotech initiated with an Outperform at Evercore ISI

Aug 10, 2026, 8:00 AM EDT - 14 days ago

Alvotech to Report Financial Results for H1 2026

Jul 29, 2026, 9:25 AM EDT - 26 days ago

Alvotech announces successful closure of FDA inspection of manufacturing facility

Jul 3, 2026, 4:01 PM EDT - 7 weeks ago

Transactions of Managers and Closely Associated Persons

Jul 1, 2026, 4:00 AM EDT - 7 weeks ago

Alvotech further strengthens liquidity by securing term loan facility of $75 million

Jun 18, 2026, 4:00 AM EDT - 2 months ago

Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement

Jun 18, 2026, 4:00 AM EDT - 2 months ago

Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares

2026-06-16T11:08:35.000Z - 2 months ago

Alvotech $152M Spot Secondary priced at $3.75

Jun 15, 2026, 11:50 PM EDT - 2 months ago

Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement

2026-06-15T22:30:37.000Z - 2 months ago

Alvotech TBA Spot Secondary; price range $3.75-$undefined

2026-06-15T20:46:20.000Z - 2 months ago

Alvotech announces termination of ATM Prospectus Supplement with Jefferies

JEF

Jun 10, 2026, 10:30 AM EDT - 2 months ago

Alvotech Transcript: UBS Virtual Generics and Biosimilars Day

Jun 8, 2026, 8:40 AM EDT - 2 months ago

Alvotech Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

2026-06-08T09:20:28.000Z - 2 months ago

Alvotech announces FDA acceptance of AVT16 BLA for review

TEVA

Jun 8, 2026, 4:00 AM EDT - 2 months ago

Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®

Jun 4, 2026, 9:20 AM EDT - 2 months ago

Alvotech Transcript: Jefferies Global Healthcare Conference 2026

2026-06-04T09:10:13.000Z - 2 months ago

Alvotech resubmits AVT05 BLAs to FDA

RDY TEVA

Jun 4, 2026, 4:00 AM EDT - 2 months ago

Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea®

Jun 3, 2026, 4:30 PM EDT - 2 months ago

Main Results of 2026 Annual and Extraordinary General Meeting

Jun 2, 2026, 4:30 PM EDT - 2 months ago

Alvotech to present at upcoming investor conferences in June

Jun 1, 2026, 4:30 AM EDT - 3 months ago

Alvotech and Islandsbanki renew Market Making Agreement for ALVO Shares Trading on Nasdaq Iceland

May 13, 2026, 6:40 PM EDT - 3 months ago

Alvotech Transcript: Bank of America Global Healthcare Conference 2026

2026-05-11T09:25:06.000Z - 3 months ago

Alvotech announces cGMP surveillance inspection of Reykjavik facility

May 11, 2026, 4:30 AM EDT - 3 months ago

Alvotech Announces Completion of FDA Surveillance Inspection at Reykjavik Facility

May 7, 2026, 8:00 AM EDT - 3 months ago

Alvotech Earnings Call Transcript: Q1 2026

May 7, 2026, 8:00 AM EDT - 3 months ago

Alvotech Earnings release: Q1 2026

May 7, 2026, 8:00 AM EDT - 3 months ago

Alvotech Slides: Q1 2026

May 6, 2026, 4:30 PM EDT - 3 months ago

Alvotech Q1 2026 Financial Results

Apr 30, 2026, 4:30 PM EDT - 4 months ago

Alvotech Announces a Change in its Executive Team

Apr 24, 2026, 8:30 AM EDT - 4 months ago

Alvotech to Report Financial Results for the First Quarter of 2026

Mar 30, 2026, 7:58 PM EDT - 5 months ago

Alvotech files Annual Report with the SEC

Mar 30, 2026, 7:55 PM EDT - 5 months ago

Alvotech Publishes 2025 Annual Report

2026-03-24T12:50:32.000Z - 5 months ago

Alvotech price target lowered to $4 from $8 at Deutsche Bank

2026-03-24T09:37:15.000Z - 5 months ago

Alvotech price target lowered to $4 from $5 at Barclays

2026-03-23T23:30:12.000Z - 5 months ago

Alvotech price target lowered to $6 from $10 at UBS

2026-03-23T18:55:10.000Z - 5 months ago

Alvotech price target lowered to $4 from $5 at Barclays

Mar 19, 2026, 8:00 AM EDT - 5 months ago

Alvotech Earnings Call Transcript: Q4 2025

Mar 19, 2026, 8:00 AM EDT - 5 months ago

Alvotech Annual report: Q4 2025

Mar 19, 2026, 8:00 AM EDT - 5 months ago

Alvotech Earnings release: Q4 2025

Mar 19, 2026, 8:00 AM EDT - 5 months ago

Alvotech Slides: Q4 2025

Mar 18, 2026, 6:15 PM EDT - 5 months ago

Alvotech Q4 2025 and Full Year 2025 Financial Results

Mar 4, 2026, 3:00 AM EST - 6 months ago

Alvotech to Report Fourth Quarter and Full Year 2025 Financial Results

Feb 11, 2026, 11:00 AM EST - 6 months ago

Alvotech Announces Increase in Number of Own Shares

Feb 5, 2026, 3:00 AM EST - 7 months ago

Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio®

Feb 2, 2026, 3:00 AM EST - 7 months ago

Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates

Jan 8, 2026, 7:00 AM EST - 8 months ago

Alvotech Slides: SEB Nordic Seminar presentation

Jan 7, 2026, 5:00 PM EST - 8 months ago

Correction: Transactions of Managers and Closely Associated Persons

2026-01-06T12:21:28.000Z - 8 months ago

Alvotech CEO Robert Wessman to step down, Lisa Graver to succeed

Dec 31, 2025, 4:30 PM EST - 8 months ago

Alvotech Secures Term Loan Facility of USD 100 Million

Dec 29, 2025, 2:40 PM EST - 8 months ago

Changes in company's own shares

Dec 22, 2025, 3:26 PM EST - 8 months ago

Alvotech's Financial Calendar for 2026

Dec 22, 2025, 2:00 AM EST - 8 months ago

Alvotech announces European launch of first-in-market biosimilar to Simponi® (golimumab) globally by partner Advanz Pharma

2025-12-19T10:06:47.000Z - 8 months ago

Alvotech, Teva reach settlement and license agreement with Regeneron for AVT06

REGN TEVA

Dec 17, 2025, 2:30 AM EST - 8 months ago

Alvotech Successfully Places USD 108 Million Senior Unsecured Convertible Bonds in a Significantly Oversubscribed Offering

Dec 16, 2025, 12:00 PM EST - 8 months ago

Alvotech Transcript: Investor Update

Dec 16, 2025, 12:00 PM EST - 8 months ago

Alvotech Press release: Investor Update

2025-12-08T21:25:13.000Z - 9 months ago

Alvotech initiated with an Underweight at Barclays

2025-12-03T11:53:22.000Z - 9 months ago

Alvotech price target lowered to $10 from $14 at Morgan Stanley

2025-11-24T10:35:12.000Z - 9 months ago

Alvotech announces European Commission approval for AVT03

Nov 24, 2025, 5:30 AM EST - 9 months ago

Alvotech Announces Approval of AVT03, a Biosimilar to Prolia® and Xgeva® (denosumab) in the European Economic Area

Nov 20, 2025, 4:00 AM EST - 9 months ago

Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab)

Nov 18, 2025, 10:30 AM EST - 9 months ago

Alvotech Transcript: Jefferies London Healthcare Conference 2025

2025-11-18T14:36:54.000Z - 9 months ago

Alvotech price target lowered to $10 from $13 at UBS

Nov 13, 2025, 8:00 AM EST - 10 months ago

Alvotech Earnings Call Transcript: Q3 2025

Nov 13, 2025, 8:00 AM EST - 10 months ago

Alvotech Earnings release: Q3 2025

Nov 13, 2025, 8:00 AM EST - 10 months ago

Alvotech Slides: Q3 2025

Nov 12, 2025, 4:40 PM EST - 10 months ago

Alvotech Reports Results for the First Nine Months of 2025 and Provides a Business Update

Nov 10, 2025, 5:28 PM EST - 10 months ago

Scott+Scott Attorneys at Law LLP Reminds Investors of Its Investigation into Alvotech (NASDAQ: ALVO)

Nov 6, 2025, 6:28 PM EST - 10 months ago

Scott+Scott Attorneys at Law LLP Alerts Investors of Its Investigation into Alvotech (NASDAQ: ALVO)

Nov 6, 2025, 9:07 AM EST - 10 months ago

Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRA

Nov 4, 2025, 4:01 PM EST - 10 months ago

Alvotech Announces Webcast on November 13, 2025 to Report Financial Results for the First Nine Months of 2025 and Provide a Business Update

2025-11-04T13:20:38.000Z - 10 months ago

Alvotech price target lowered to $10 from $28 at Northland

Nov 2, 2025, 5:12 PM EST - 10 months ago

Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05

Oct 22, 2025, 5:00 AM EDT - 10 months ago

Alvotech Announces Changes in Global Business Development and Commercial Operations Team

Oct 6, 2025, 4:40 AM EDT - 11 months ago

European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency

Sep 22, 2025, 6:15 AM EDT - 1 year ago

European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech's Proposed Biosimilar to Prolia® and Xgeva®

time_to_snap Aug. 24 at 5:12 PM

0 · Reply

notreload_ai Aug. 24 at 4:21 PM

0 · Reply

G101SPM Aug. 24 at 3:59 PM

$ALVO $5.15 +0.72 Alvotech (ALVO) initiated with a Buy at BofA Securities, tgt $7 note: ) The Company signs Lotus Pharma deal for durvalumab and emicizumab biosimilars in U.S. and parts of Asia.

0 · Reply

JohnTill Aug. 24 at 3:37 PM

0 · Reply

time_to_snap Aug. 24 at 3:20 PM

$ALVO 🚀🚀🚀

0 · Reply

JohnTill Aug. 24 at 3:10 PM

0 · Reply

JohnTill Aug. 24 at 2:05 PM

1 · Reply

FlyingChemist01 Aug. 24 at 1:26 PM

$ALVO I'm quite surprised of this price action, I wasnt expecting this surge.

2 · Reply

Windy007 Aug. 24 at 11:12 AM

0 · Reply

JohnTill Aug. 21 at 2:27 PM

0 · Reply

notreload_ai Aug. 21 at 2:15 PM

$ALVO partners with Lotus for biosimilars to Imfinzi and Hemlibra in the US and Asia. Deal worth up to $150M plus ongoing supply revenue. https://notreload.xyz/xy/alvotech-lotus-partner-on-imfinzi-hemlibra-biosimilars/

0 · Reply

Rybod30 Aug. 21 at 1:58 PM

$ALVO That news is certainly worth more than $.20, but market says eh🤷‍♂️😬…

0 · Reply

88Nate Aug. 21 at 1:48 PM

$ALVO I’m in🦾

1 · Reply

Rybod30 Aug. 21 at 1:46 PM

$ALVO Weak $.30 flag in process of likely failing, but🤷‍♂️😬..

0 · Reply

Rybod30 Aug. 21 at 1:39 PM

$ALVO Sellers at $4.60…

0 · Reply

Rybod30 Aug. 21 at 1:38 PM

$ALVO Great PR, just can’t get any attention☹️

0 · Reply

RAIK7 Aug. 21 at 1:05 PM

$ALVO https://www.stocktitan.net/news/ALVO/alvotech-announces-licensing-and-commercialization-agreement-with-1ewz36m2332u.html

1 · Reply

JohnTill Aug. 20 at 6:50 PM

$ALVO This was my third largest position and a low 3 avg for round two. I really like they held estimates but still locked in a bunch today at 4.25-4.35 today for no other reason than lock in profits and provide me room to add if we dip again give December is long ways away and Sept-Oct. might be an ugly market. Still have a decent clip in case we never look back for the gap fill.

0 · Reply

Kosmokrat Aug. 20 at 2:34 PM

$ALVO I had hoped for better revenue numbers. Good news is that they confirmed the current forecast for the year. I just hope the 3 launches will happen as planned either this year or very early next year. I also hope that product sales will pick up significantly from here on. They will need a lot more revenue for H2 to meet their forecast. Overall I am still very bullish on $ALVO, but now they have to deliver on their promises.

0 · Reply

EarningsInsider Aug. 20 at 2:01 PM

https://www.marketbeat.com/earnings/reports/2026-8-20-alvotech-stock/ $ALVO Alvotech Earnings Transcript

0 · Reply

Icarium Aug. 19 at 9:05 PM

$ALVO nothing out of the ordinary. Have conferences in Sept that may provide additional info. Interesting to see guidance unchanged, and we'll see if they can meet those targets. Quite the gap to close in the back half of the year, and will show if management is being honest with their projections.

2 · Reply

StocktwitsEarnings Aug. 19 at 8:43 PM

$ALVO Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.22 down -300.00% YoY • Reported revenue of $105.77M down -38.93% YoY • Alvotech management anticipates total revenues to be in the range of $650-$700 million and adjusted EBITDA to be in the range of $180-220 million for the full year of 2026.

0 · Reply

Market Cap	1.34B
Revenue (ttm)	586.32M
Net Income (ttm)	27.92M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	88.64
Profit Margin	4.76%
Debt to Equity Ratio	-4.64

Volume	2,638,310
Avg Vol	906,694
Day's Range	N/A - N/A
Shares Out	301.81M
Stochastic %K	80%
Beta	0.18
Analysts	Sell
Price Target	$5.75